The plant, located in the town of Alzey in Rhineland-Palatinate, will serve the company’s growing demand for diabetes drugs and the recent obesity remedies Mounjaro and Zepbound.
Ilya Yuffa, president of Lilly International, said the investment aims to “usher in a new era of collaboration and innovation in Germany and the EU, through our shared purpose of finding sustainable answers for patients. “
Lilly said it plans to use automation and high-speed production lines to increase productivity.
The move is part of an $11 billion investment program Lilly has made in production facilities over the past three years. The company said it will continue to invest in expanding its global production to meet expected growth in new drugs to treat diabetes and obesity, Alzheimer’s. diseases, cancer, and autoimmune diseases.
Robert Habeck, Germany’s economy minister, Lilly’s move would create “future-oriented jobs. “
“The new one will make a decisive contribution to the creation of commercial prices in Germany through high-tech production, studies and development facilities,” he said.
Construction will begin next year and the plant is expected to be operational in 2027.
Other readings: